Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DA-007 · 1 trial · 2 indications
Amount of hair loss during chemotherapy treatment measured by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0. The Common Terminology Criteria for Adverse Events is a common terminology developed by the National Cancer Institute to describe and grade adverse events related to cancer therapy.
| Arm | Type | Description |
|---|---|---|
| DA-007 | ACTIVE_COMPARATOR | Topical DA-007 Solution |
| Placebo | PLACEBO_COMPARATOR | Topical Placebo Solution |
| Name | Type | Description |
|---|---|---|
| DA-007 | DRUG | Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine |
| Placebo | DRUG | Topical placebo solution |
Inclusion Criteria: * Diagnosed with stage I or stage II breast cancer * Scheduled but not begun, at least 4 cycles of taxane and/or anthracycline-based chemotherapy. * Ages 18-65 * Able to give informed consent Exclusion Criteria: * Resting blood pressure outside the range of 105-140/ 55-99 * Un...
DA-007 is an investigational small molecule being developed for the treatment of chemotherapy induced alopecia, a condition characterized by hair loss as a side effect of chemotherapy. It is currently in Phase 3 clinical development and has not yet been approved by regulatory authorities.
DA-007 is being developed by Applied Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol APLT. The company is conducting a Phase 3 clinical trial to evaluate the drug's efficacy and safety in patients with chemotherapy induced alopecia.
DA-007 is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 3 trial is designed to assess its effectiveness in treating chemotherapy induced alopecia.
DA-007 is being evaluated in a Phase 3 clinical trial with the identifier NCT06762548. This randomized, double-blind, placebo-controlled study is planned to enroll 140 female participants aged 18 years and older in Italy. The trial is not yet recruiting and will assess the drug for chemotherapy induced alopecia.
DA-007 is the primary name used for this investigational drug in clinical development. No alternative names have been reported for this compound. It is being studied specifically for its potential to treat chemotherapy induced alopecia.